Abstract
Background: Haemophilia is an inherited bleeding disorder due to failure of throm-bin generation resulting from clotting factor deficiency. In haemophilia A, the de-ficient factor is Factor VIII due to mutations in the F8 gene. In the past several
 decades, we have seen an unprecedented evolution of therapies for managing hae-mophilia A (Mahlangu, 2022) . These have included blood and blood products to
 plasma-derived concentrate, recombinant concentrate, concentrate with improvedpharmacokinetics and, more recently, non-replacement therapies. Notwithstandingthese advances in treatments, patients with haemophilia A (PwHA) remain withseveral unmet needs.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JORNAL DE ASSISTÊNCIA FARMACÊUTICA E FARMACOECONOMIA
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
